Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022;9(2):190-192.
doi: 10.14283/jpad.2022.36.

Editorial: The 'Aducanumab Story': Will the Last Chapter Spell the End of the 'Amyloid Hypothesis' or Mark a New Beginning?

Z S Khachaturian  1
Affiliations
Editorial

Editorial: The 'Aducanumab Story': Will the Last Chapter Spell the End of the 'Amyloid Hypothesis' or Mark a New Beginning?

Z S Khachaturian. J Prev Alzheimers Dis. 2022.
No abstract available

PubMed Disclaimer

Conflict of interest statement

ZS Khachaturian is: Editor-in-Chief, Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association; Senior Science Advisor: Alzheimer’s Association; President of Prevent Alzheimer’s Disease 2020 [PAD2020.org]; Member of board: Care Weekly / Khachaturian and Associates Inc.; Received reimbursement – for travel to meeting: Alzheimer’s Association and Acadia Pharmaceuticals /for participation on an Ethics Advisory meeting: Biogen.

Comment on

  • Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
    Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Budd Haeberlein S, et al. J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30. J Prev Alzheimers Dis. 2022. PMID: 35542991 Clinical Trial.

LinkOut - more resources